natgillin/translations-raw huggingface dataset:
The patch is a clear plastic with an adhesive backing, protected by a release liner that is to be removed prior to application.
Flaster izrađen od prozirne plastike s adhezivnim potpornim slojem, zaštitnim slojem koji se treba ukloniti prije primjene.
Discard the protective liners.
- Bacite zaštitni sloj.
Kentera is not recommended for use in children or adolescents.
Ne preporučuje se primjena Kentere u djece ili adolescenata.
The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride.
Oksibutinin u obliku slobodne baze farmakološki je ekvivalentan oksibutininkloridu.
Kentera is a transdermal patch and it is packaged in cartons containing 2, 8, and 24 patches.
Kentera je transdermalni flaster i pakira se u kutije koje sadrže 2, 8 i 24 flastera.
EU/1/03/270/004 <30 sachets>
EU/1/03/270/004 <30 vrećica>
A total of 957 patients with urge urinary incontinence were evaluated in three controlled studies comparing Kentera to either placebo, oral oxybutynin and/or tolterodine long acting capsules.
Ukupno je 957 bolesnika s urgentnom urinarnom inkontinencijom evaluirano u tri kontrolirana ispitivanja u kojima je Kentera uspoređena s placebom, peroralnim oksibutininom i/ili s kapsulama tolterodina s produljenim oslobađanjem.
Keep application sites covered with clothing when coming into contact with breast-feeding women or nursing babies.
Držite mjesta primjene pokrivena odjećom kada dolazite u kontakt s dojiljama ili dojenom djecom.
Kentera delivers approximately 0.08 mg/kg/day.
0,08 mg/kg/dan.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SACHET (Contains 1 transdermal patch)
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE VREĆICA (Sadrži 1 transdermalni flaster)
Before using the pump for the first time the multidose container should be primed.
Prije prvog korištenja pumpice potrebno je pripremiti višedozni spremnik.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Učestalosti su definirane na sljedeći način: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000).
Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin, which is pharmacologically active.
Metaboliti uključuju fenil-cikloheksil-glikolnu kiselinu, koja je farmakološki neaktivna, i N-desetiloksibutinin, koji je farmakološki aktivan.
The used patches should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of the reach of children.
Iskorištene flastere treba saviti napola, ljepljivom stranom prema unutra tako da membrana koja otpušta lijek nije izložena, staviti u originalnu vrećicu i zatim zbrinuti na siguran način izvan dohvata djece.
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.
Transdermalna primjena oksibutinina zaobilazi metabolizam prvog prolaza kroz gastrointestinalni trakt i jetru, smanjujući stvaranje metabolita N-desetila.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Osim toga, manje od 0,1% primijenjene doze izlučuje se kao metabolit
It is recommended to cover the application site with clothing once the gel has dried.
Preporučuje se pokrivanje mjesta primjene odjećom nakon što se gel osušio.
Rings of adhesive that become soiled may require a medical adhesive removal pad that should be available from your pharmacist.
Za uklanjanje krugova ljepila koji su se zaprljali možda bude potrebno koristiti kompresu za uklanjanje medicinskog ljepila koju možete nabaviti kod ljekarnika.
Your urge incontinence may return and you may have increased urinary frequency if you decide to stop using the gel.
Urgentna inkontinencija mogla bi se vratiti i mogli biste imati povećanu učestalost mokrenja ako odlučite prestati primjenjivati gel.
The use of Kentera in patients with hepatic impairment should be carefully monitored since oxybutynin is extensively hepatic metabolised.
Primjenu Kentere u bolesnika s oštećenjem jetre potrebno je pažljivo pratiti zato što se oksibutinin opsežno metabolizira u jetri.
See leaflet for further information.
Dodatne informacije.
The recommended dose is one sachet applied once daily which corresponds to a delivery dose of approximately 4 mg.
Preporučena doza je jedna vrećica primijenjena jedanput dnevno, što odgovara isporučenoj dozi od približno 4 mg.
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/kg was identified.
U ispitivanju supkutane primjene i plodnosti kod štakora, nisu primijećeni poremećaji kod mužjaka, no kod ženki je poremećena plodnost, a NOAEL (najviša doza bez zapaženog štetnog učinka) je identificiran pri 5 mg/kg.
The area of the patch is 39 cm2, releasing a nominal 3.9 mg of oxybutynin per 24 hours.
Površina flastera je 39 cm2, a oslobađa nominalno 3,9 mg oksibutinina tijekom 24 sata.
Pharmacotherapeutic group: Urologicals, urinary antispasmodics, ATC code: G04B D04.
Farmakoterapijska skupina: Urološki lijekovi, urinarni spazmolitici, ATK oznaka: G04B D04.
How to apply
Kako se primjenjuje
Rapid drying, clear, smooth, odourless, and colourless hydroalcoholic gel.
Brzosušeći, prozirni, glatki, bezmirisni i bezbojni hidroalkoholni gel.
Kentera is contraindicated in patients with urinary retention, severe gastro-intestinal condition, myasthenia gravis or narrow-angle glaucoma and in patients who are at risk for these conditions.
Kentera je kontraindicirana u bolesnika s urinarnom retencijom, teškim gastrointestinalnim bolestima, miastenijom gravis ili glaukomom zatvorenog kuta te u bolesnika kod kojih postoji rizik od takvih bolesti.
perspiration and digestion - Problems with memory, language, or thinking abilities - A progressive neurological disease characterised by tremor of resting muscles, rigidity,
- problemi s pamćenjem, jezikom ili sa sposobnošću razmišljanja - progresivna neurološka bolest koju karakterizira drhtanje mišića u mirovanju, ukočenost,
If prime is lost during the use (no gel is dispensed after depressing the pump), repeat as instructed above to re-prime the pump.
Ako se tijekom uporabe dogodi da pumpica ne oslobađa odmjerenu dozu (nije dostavljen gel nakon pritiska na pumpicu), ponovite gore navedene upute da biste ponovno pripremili pumpicu.
Upper respiratory tract infection, fungal infection
Infekcije gornjih dišnih putova, gljivične infekcije
Oral administration of oxybutynin may warrant the following cautionary statements, but these events were not observed during clinical trials with Kentera:
Peroralna primjena oksibutinina može opravdati sljedeća upozorenja, ali ti slučajevi nisu zapaženi tijekom kliničkih ispitivanja s Kenterom:
Oxybutynin may exacerbate the symptoms of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, hypertension and prostatic hypertrophy
Oksibutinin može pogoršati simptome hipertireoze, koronarne bolesti srca, kongestivnog zatajenja srca, srčanih aritmija, tahikardije, hipertenzije i hipertrofije prostate.
The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet.
Flaster treba primijeniti na suhu, zdravu kožu abdomena, kuka ili stražnjice odmah nakon uklanjanja zaštitne vrećice.
Each patch of 39 cm2 contains 36 mg of oxybutynin.
Jedan flaster od 39 cm2 sadrži 36 mg oksibutinina.
- The other ingredients are: ethanol (96%), glycerol, hydroxypropylcellulose, sodium hydroxide (for pH adjustment), and purified water.
Drugi sastojci su: etanol (96%), glicerol, hidroksipropilceluloza, natrijev hidroksid (za podešavanje pH) i pročišćena voda.
Kentera contains the active substance oxybutynin and is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Kentera sadrži djelatnu tvar oksibutinin i primjenjuje se u odraslih za kontrolu simptoma urgentne inkontinencije i/ili povećane učestalosti mokrenja i urgentnog mokrenja.
Hence, after removal, the used patch should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of reach of children.
Stoga, nakon uklanjanja, iskorišteni flaster treba saviti napola, s ljepljivom stranom prema unutra tako da membrana koja otpušta lijek nije izložena, vratiti u originalnu vrećicu i zatim zbrinuti na siguran način izvan dohvata djece.
The multidose container is comprised of an outer polypropylene bottle with a Low Density Polyethylene (LDPE) pouch liner, a polypropylene metering pump, with ethylene propylene diene monomer (EPDM) gaskets, and a polypropylene cap.
Višedozni spremnik sastoji se od vanjske polipropilenske boce sa zaštitnom vrećicom od polietilena niske gustoće (LDPE), odmjerne pumpice od polipropilena, s brtvama od etilenpropilendien monomera (EPDM), i polipropilenskog zatvarača.
Your urge incontinence may return and you may have increased urinary frequency if you decide to stop using the patch.
Urgentna inkontinencija mogla bi se vratiti i mogli biste imati povećanu učestalost mokrenja ako odlučite prestati primjenjivati flaster.
Kentera is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Kentera se primjenjuje u odraslih za kontrolu simptoma urgentne inkontinencije i/ili povećane učestalosti mokrenja i urgentnog mokrenja.
Reductions in weekly incontinence episodes, urinary frequency, and urinary void volume were evaluated.
Evaluirano je smanjenje tjednih epizoda inkontinencije, učestalosti mokrenja i volumena izmokrene mokraće.
To prime the pump, fully depress the pump mechanism repeatedly until gel is observed, then depress the pump one more time, and discard this portion of the medicinal product to assure precise dose delivery.
Za pripremu pumpice, više puta potpuno pritisnite mehanizam pumpice, dok ne primijetite gel, zatim pritisnite pumpicu još jednom i bacite taj dio lijeka kako biste osigurali preciznu isporuku doze.
Pharmacotherapeutic group: urinary antispasmodic, ATC code: G04B D04.
Farmakoterapijska skupina: urinarni spazmolitik, ATK oznaka: G04B D04.
- Phenothiazines or clozapine (used to treat mental illness).
- fenotiazini ili klozapin (primjenjuju se za liječenje duševne bolesti)
Store pump in the upright position.
Čuvati pumpicu u uspravnom položaju.
Press down on the liner firmly.
Čvrsto pritisnite zaštitni sloj prema dolje.
The oxybutynin, triacetin and acrylic adhesive are coated on clear PET/EVA backing film and covered with a siliconised polyester release liner.
Oksibutinin, triacetin i akrilno ljepilo su naneseni na prozirni potporni sloj PET/EVA i prekriveni zaštitnim slojem od silikoniziranog poliestera.
Following the application of Kentera, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/ml.
Nakon primjene Kentere, koncentracija oksibutinina u plazmi povećava se tijekom približno 24 do 48 sati i dostiže prosječnu maksimalnu koncentraciju od 3 do
Please read all the information below before you begin to apply Kentera.
Pročitajte sve informacije u nastavku prije nego što počnete primjenjivati Kenteru.
The safety of Kentera was evaluated in patients with urge urinary incontinence in a randomised, double-blind, placebo-controlled, parallel group Phase 3 study that included 789 patients (with 389 patients receiving Kentera and 400 patients receiving placebo).
Sigurnost Kentere ocijenjena je u bolesnika s urgentnom urinarnom inkontinencijom u randomiziranom, dvostruko slijepom, placebo kontroliranom ispitivanju faze III s usporednom skupinom koja je obuhvaćala 789 bolesnika (od kojih je 389 bolesnika primjenjivalo Kenteru, a 400 bolesnika placebo).
Travel subscale
Podljestvica putovanja
Mean and median change from baseline in daily incontinence episodes (primary endpoint), urinary frequency, and urinary void volume between placebo and active treatment groups are summarised in the table below.
Srednja vrijednost i medijan promjene od početne vrijednosti u dnevnim epizodama inkontinencije (primarna mjera ishoda), učestalosti mokrenja i volumenu izmokrene mokraće između skupine koja je primala placebo i skupine koja je primala aktivnu terapiju sažete su u tablici u nastavku.
Application should not be made to the same site on consecutive days.
Primjena se ne smije ponoviti na istom mjestu sljedećeg dana.
Gently rub Kentera into your skin until it dries.
4. korak Nježno utrljajte Kenteru u kožu dok se ne osuši.
It is recommended to cover the application site with clothing once Kentera has dried.
Preporučuje se pokrivanje mjesta primjene odjećom nakon što se Kentera osušila.
PARTICULARS TO APPEAR ON THE OUTER AND THE IMMEDIATE PACKAGING MULTIDOSE CONTAINER WITH METERING PUMP
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM I UNUTARNJEM PAKOVANJU VIŠEDOZNI SPREMNIK S ODMJERNOM PUMPICOM
Do not use if seal on sachet is broken
Ne upotrebljavajte ako je vrećica oštećena.
Oxybutynin thus decreases urinary urgency and the frequency of both incontinence episodes and voluntary urination.
Oksibutinin stoga smanjuje urgentno mokrenje i učestalost epizoda inkontinencije i voljnog mokrenja.
You should wear each patch all the time until you apply a new one.
Svaki flaster je potrebno držati na sebi cijelo vrijeme, sve do primjene novog flastera.
Kentera should be used with caution in elderly patients, who may be more sensitive to the effects of centrally acting anticholinergics and exhibit differences in pharmacokinetics.
Kenteru je potrebno primjenjivati uz oprez u starijih bolesnika, koji mogu biti osjetljiviji na učinke centralno djelujućih antikolinergika i pokazivati razlike u farmakokinetici.
There are no adequate data on the use of oxybutynin transdermal patch in pregnant women.
Ne postoje adekvatni podaci o primjeni transdermalnog flastera oksibutinina kod trudnica.
Oral administration of oxybutynin may warrant the following cautionary statements, but these events were not observed during clinical trials with Kentera.
Peroralna primjena oksibutinina može opravdati sljedeća upozorenja, ali ti slučajevi nisu zapaženi tijekom kliničkih ispitivanja s Kenterom.
Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems.
Iskorišteni flasteri ne smiju se baciti u kanalizaciju niti odlagati putem sustava za zbrinjavanje tekućeg otpada.
EU/1/03/270/005 <1 multidose container with metering pump>
EU/1/03/270/005 <1 višedozni spremnik s odmjernom pumpicom>
Total score
Ukupan rezultat
Figure A:
Slika A:
The Phase 3 study was a randomised, double-blind, placebo-controlled, parallel group study that included 789 patients.
Ispitivanje faze III bilo je randomizirano, dvostruko slijepo, kontrolirano placebom, s usporednom skupinom i obuhvaćalo je 789 bolesnika.
Mechanism of action: oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
Mehanizam djelovanja: oksibutinin djeluje kao kompetitivni antagonist acetilkolina na razini postganglijskih muskarinskih receptora, što rezultira relaksacijom glatkih mišića mjehura.
Adverse reactions considered associated with anticholinergic therapy,in general or observed with oral administration of oxybutynin, but as of yet not with Kentera in clinical trials or post-marketing, are: anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, paranoia, photosensitivity, erectile dysfunction.
Nuspojave koje se smatraju općenito povezane s antikolinergičkom terapijom ili su opažene uz peroralnu primjenu oksibutinina, ali još nisu primijećene uz Kenteru u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet, jesu anoreksija, povraćanje, refluksni ezofagitis, smanjeno znojenje, toplinski udar, smanjeno suzenje, midrijaza, tahikardija, aritmija, noćne more, nemir, konvulzije, intraokularna hipertenzija i induciranje glaukoma, paranoja, fotoosjetljivost, erektilna disfunkcija.
Excipients: ethanol (96%), glycerol, hydroxypropylcellulose, sodium hydroxide (for pH adjustment), and purified water.
Pomoćne tvari: etanol (96%), glicerol, hidroksipropilceluloza, natrijev hidroksid (za podešavanje pH) i pročišćena voda.
Postmarketing adverse reactions not seen in clinical trials are also included.
Obuhvaćene su i nuspojave zabilježene nakon stavljanja lijeka u promet koje nisu primijećene u kliničkim ispitivanjima.
The application site may be covered with clothing once Kentera has dried.
Mjesto primjene smijete pokriti odjećom nakon što se Kentera osušila.
Kentera should be applied to dry, intact skin on the abdomen, upper arms/shoulders, or thighs.
Kenteru je potrebno primijeniti na suhu, neozlijeđenu kožu abdomena, nadlaktice/ramena ili bedra.
Only apply Kentera to intact skin.
Primijenite Kenteru na neozlijeđenu kožu.
After applying Kentera, immediately wash your hands thoroughly with soap and water.
5. korak: Nakon primjene Kentere, odmah temeljito operite ruke sapunom i vodom.
Oxybutynin is extensively metabolised by the liver, see above, with less than 0.1% of the administered dose excreted unchanged in the urine.
Oksibutinin se opsežno metabolizira u jetri, kao što je gore opisano, a manje od 0,1% primijenjene doze izlučuje se u mokraći u neizmijenjenom obliku.
Kentera is a rapid drying, clear, smooth, odourless, and colourless hydroalcoholic gel that is packaged in single dose sachets.
Kentera je brzosušeći, prozirni, glatki, bezmirisni i bezbojni hidroalkoholni gel pakiran u vrećicama za jednokratnu dozu.
There is no experience with the use of Kentera in patients with hepatic impairment.
Nema iskustva s primjenom Kentere u bolesnika s oštećenjem jetre.
- Phenothiazines, butyrophenone or clozapine (used to treat mental illness).
- fenotiazini, butirofenon ili klozapin (primjenjuju se za liječenje duševne bolesti)
Backing: polyester/ethylene-vinyl acetate film; siliconised polyester film.
Potporni sloj: sloj poliester/etilen-vinilacetata; sloj silikoniziranog poliestera.
Discard empty sachets and unused product in accordance with local requirements.
Zbrinuti prazne vrećice i neiskorišteni lijek sukladno lokalnim propisima.
Oxybutynin may slow the digestive tract and thereby influence the adsorption of other oral medicines, or the use of this medicine together with other medicines may increase the effect of oxybutynin.
Oksibutinin može usporiti probavni trakt i stoga utjecati na apsorpciju drugih lijekova koji se uzimaju kroz usta (peroralno), ili primjena tog lijeka zajedno s drugim lijekovima može pojačati učinak oksibutinina.
EU/1/03/270/001 <8 transdermal patches> EU/1/03/270/002 <24 transdermal patches> EU/1/03/270/003 <2 transdermal patches>
EU/1/03/270/001 <8 transdermalnih flastera> EU/1/03/270/001 <24 transdermalna flastera> EU/1/03/270/001 <2 transdermalna flastera>
Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
Oksibutinin djeluje kao kompetitivni antagonist acetilkolina na razini postganglijskih muskarinskih receptora, što rezultira relaksacijom glatkih mišića mjehura.
EU/1/03/270/005 1 multidose container with metering pump
EU/1/03/270/005 1 višedozni spremnik s odmjernom pumpicom
As oxybutynin is metabolised by cytochrome P 450 isoenzyme CYP 3A4, interactions with medicinal products that inhibit this isoenzyme cannot be ruled out.
Budući da se oksibutinin metabolizira putem izoenzima CYP3A4 citokroma P450, ne može se isključiti interakcija s lijekovima koji inhibiraju taj izoenzim.
The recommended dose is one metered dose from the multidose container with metering pump applied once daily which corresponds to a delivery dose of approximately 4 mg.
Preporučena doza je jedna odmjerena doza iz višedoznog spremnika s odmjernom pumpicom primijenjena jedanput dnevno, što odgovara isporučenoj dozi od približno 4 mg.
Use with sunscreen
Korištenje s preparatima za zaštitu od sunca
Each transdermal patch contains 36 mg of oxybutynin.
Jedan transdermalni flaster sadrži 36 mg oksibutinina.
Avoid bathing, swimming, showering, exercising or immersing the application site in water for one hour after application.
Nemojte se kupati, plivati, tuširati, vježbati ili uranjati mjesto primjene u vodu jedan sat nakon primjene.
The concomitant use of oxybutynin with other anticholinergic medicinal products or with other active substances that compete for CYP3A4 enzyme metabolism may increase the frequency or severity of dry mouth, constipation, and drowsiness.
Istodobna primjena oksibutinina s drugim antikolinergičkim lijekovima ili s drugim djelatnim tvarima koje se natječu za metabolizam enzima CYP3A4 može povećati učestalost ili težinu suhoće usne šupljine, konstipacije i omamljenosti.
Placebo)
bolesnika placebo).
Before using the pump for the first time, you must prime the Kentera pump.
1. korak: Prije prvog korištenja pumpice potrebno je pumpicu Kentera pripremiti.
Gastrointestinal disorders: Anticholinergic medicinal products may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention.
Gastrointestinalni poremećaji: Antikolinergički lijekovi mogu usporiti gastrointestinalni motilitet i potrebno ih je primjenjivati uz oprez u bolesnika s gastrointestinalnim opstruktivnim poremećajima zbog rizika od želučane retencije.
Use of oxybutynin is not recommended during breast-feeding.
Primjena oksibutinina ne preporučuje se tijekom dojenja.
EU/1/03/270/001 8 transdermal patches EU/1/03/270/002 24 transdermal patches EU/1/03/270/003 2 transdermal patches
EU/1/03/270/001 8 transdermalnih flastera EU/1/03/270/002 24 transdermalna flastera EU/1/03/270/003 2 transdermalna flastera
Abdominal discomfort, dyspepsia
Nelagoda u abdomenu, dispepsija
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Simptomatsko liječenje urgentne inkontinencije i/ili povećane učestalosti mokrenja i urgentnog mokrenja koji se može pojaviti u odraslih bolesnika s nestabilnim mokraćnim mjehurom.
If applying Kentera to the stomach, care should be taken to avoid the area around the navel (belly button).
Ako primjenjujete Kenteru na trbuh, pazite da je ne stavite na područje oko pupka.
Oxybutynin may slow the digestive tract and thereby influence the adsorption of other oral medicines, interfere with bowel movement therapies, and the use of this medicine together with other medicines may increase the effect of oxybutynin.
Oksibutinin može usporiti probavni trakt i stoga utjecati na apsorpciju drugih lijekova koji se uzimaju kroz usta (peroralno), utjecati na terapije za pražnjenje crijeva, a primjena tog lijeka zajedno s drugim lijekovima može pojačati učinak oksibutinina.
- Overactive thyroid gland which can cause increased appetite, weight loss, or sweating - Narrowing of the blood vessels that supply blood and oxygen to the heart - Heart problems which can cause shortness of breath or ankle swelling - Irregular heart beat - Faster heart beat - High blood pressure - Enlarged prostate
- prekomjerno aktivna štitna žlijezda koja može prouzročiti povećani apetit, gubitak tjelesne težine, ili znojenje - sužavanje krvnih žila koje dostavljaju krv i kisik srcu - problemi sa srcem koji mogu prouzročiti nedostatak zraka ili oticanje gležnjeva - nepravilni otkucaji srca - ubrzani otkucaji srca - visok krvni tlak - povećana prostata.
Kentera is a rapid drying, clear, smooth, odorless, and colorless hydroalcoholic gel that is packaged in a multidose container with metering pump.
Kentera je brzosušeći, prozirni, glatki, bezmirisni i bezbojni hidroalkoholni gel pakiran u višedoznom spremniku s odmjernom pumpicom.